Abnormal activation of endochondral bone formation in soft tissues causes significant medical diseases associated with disability and pain. Hyperactive mutations in the bone morphogenetic protein (BMP) type 1 receptor ACVR1 lead to fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive ossification in soft tissues. However, the specific cellular mechanisms are unclear. In addition, the difficulty obtaining tissue samples from FOP patients and the limitations in mouse models of FOP hamper our ability to dissect the pathogenesis of FOP.
To address these challenges and develop a “disease model in a dish”, we created human induced pluripotent stem cells (iPS cells) derived from normal and FOP dermal fibroblasts by two separate methods, retroviral integration or integration-free episomal vectors. We tested if the ability to contribute to different steps of endochondral bone formation was different in FOP vs. control iPS cells.
Remarkably, FOP iPS cells showed increased mineralization and enhanced chondrogenesis in vitro. The mineralization phenotypes could be suppressed with a small-molecule inhibitor of BMP signaling, DMH1. Our results indicate that the FOP ACVR1 R206H mutation favors chondrogenesis and increases mineral deposition in vitro.
Our findings establish a FOP disease cell model for in vitro experimentation and provide a proof-of-concept for using human iPS cell models to understand human skeletal disorders.
Induced pluripotent stem cellsFibrodysplasia ossificans progressivaFOPDisease model in a dishEndochondral ossification
Tissue mineralization is one of the most dramatic transitions in normal development and disease. Hard tissues, such as bone and teeth, maintain body structure, protect vital organs, and facilitate eating. Abnormal activation of endochondral bone formation in soft tissues from congenital disorders, such as fibrodysplasia ossificans progressiva (FOP; OMIM #135100) or from trauma or central nervous system injury  cause severe disability and pain. Although bone morphogenetic proteins (BMPs) are key regulators of osteogenesis  and are implicated in pathologic calcification , their specific functions in humans are not well understood. Human induced pluripotent stem cells (iPS cells) derived from patients with genetic mutations affecting key signaling pathways provide a unique opportunity to dissect human development and disease pathogenesis in models amenable to experimental manipulation .
FOP is a rare but debilitating disease of heterotopic bone formation associated with mutations in the Activin A Type I receptor (ACVR1) , which is activated by BMPs. A single amino acid change (R206H) commonly resulting from a single base mutation (617G > A) is found in the majority of FOP patients and can increase sensitivity of the receptor to BMP ligands . Patients are born without heterotopic ossification yet characteristically form large amounts of bone either spontaneously or after trauma . The heterotopic ossification follows an endochondral bone formation pathway that starts with a pre-cartilaginous fibro-proliferative anlage and eventually mineralizes. The ferocity of these episodes makes it nearly impossible to obtain tissue samples prospectively and significantly complicates surgical management.
Here, we created a series of iPS cells from dermal fibroblasts of donors with FOP by either DNA-integrating retroviral or integration-free episomal plasmid methods [4, 8]. The FOP iPS cells showed increased mineral deposition and chondrogenesis, potentially reflecting a predisposition towards endochondral bone formation in FOP. Our findings provide a valuable foundation for human stem cell-based systems to delineate the mechanisms of normal and pathologic skeletal formation.
Materials and methods
Primary human dermal fibroblasts (HDFs) from commercial sources or from 3-mm skin biopsies carefully obtained from donors (without causing deep tissue injury) or from surgical excess were cultured  and are described in Table 1 and Additional file 1: Table S1. HDFs less than five passages old were used for iPS cell reprogramming. Presence or absence of the ACVR1 mutation was sequenced and verified as described . Primary human mesenchymal stem cells (hMSCs) were prepared from iliac bone as described previously  and expanded as a monolayer.
Cell lines used in this study
Human dermal fibroblasts
Foreskin (Stemgent 08–0027)
Fibroblast (Cell Applications, 1323)
Fibroblast (Cell Applications, 1388)
Collection of Research Bioresources, Japan
Skin Fibroblast, Corielle GM00513
Skin Fibroblast, Corielle GM00783
Control retroviral iPS cell lines (wildtype ACVR1)*
FOP retroviral iPS cell lines (ACVR1 R206H)*
Control episomal iPS cell lines (Wildtype ACVR1)**
FOP episomal iPS cell lines (ACVR1 R206H)**
Summary of the FOP and control human dermal fibroblasts and iPS cell lines used in this study, including naming, classification (control vs. FOP), and original tissue source. HDF, human dermal fibroblast; FF, foreskin fibroblast. Please see Additional file 1: Table S1 for a detailed summary of the iPS cell characterization. Method of making iPS cells: *, Retroviral OSKM ; **, Epi(Y4).
Retroviral  and episomal integration-free  iPS cells were derived as described. H9 human embryonic stem (ES) cells were from WiCell Research Institute (Madison, WI). All pluripotent cell lines were maintained in mTeSR1 medium (StemCell Technologies, Vancouver, Canada) on growth-factor-reduced Matrigel (BD Biosciences)-coated plates (150–300 μg/ml, 30 min coating) or in primate ES cell medium (ReproCELL, Tokyo, Japan) on mitomycin C-treated or irradiated SNL feeder cells . SNLs were carefully removed by at least one passage in feeder-free conditions before use in differentiation assays. The ROCK inhibitor Y-27632 (10 μM, Tocris Bioscience, Minneapolis, MN) dissolved in DMSO was added to mTeSR1 at passaging and removed the following day. Karyotyping was done by Cell Line Genetics (Madison, WI) or Nihon Gene Research Laboratories (Sendai, Japan). Cells exposed to recombinant BMP4 protein (R&D Systems, Minneapolis, MN) were treated for 45 minutes.
All human tissue collection, human stem cell studies, procedures, and written consents were approved by the UCSF Committee on Human Research, the UCSF Gamete and Embryonic Stem Cell Research Committee, or by the Ethics Committee of the Department of Medicine and Graduate School of Medicine, Kyoto University.
Embryoid body formation
Embryoid bodies (EBs) were formed from iPS cells or human ES cells once their cultures reached 80% confluence. After washing with PBS, Accutase (StemCell Technologies, Vancouver, Canada) was applied for two minutes to remove cells from the plate. Cells were centrifuged at 175 × g for two minutes and then resuspended in a 4:1 mix of EB differentiation medium (80% Knockout DMEM, 20% FBS, 1% Glutamax, 1% non-essential amino acids, and 0.1 mM 2-mercaptoethanol) and mTeSR1, and supplemented with 10 μM Y-27632. Cells were plated onto ultra-low attachment plates without medium changes for seven days. On day eight, EBs were collected and allowed to settle in a conical tube for 30 minutes. The mixed medium was removed and replaced with 100% EB differentiation medium (Knockout DMEM supplemented with 20% FBS, 1% Glutamax, 1% non-essential amino acids, and 0.1 mM 2-mercaptoethanol) changed every three to four days. EBs were then transferred to gelatinized plates and cultured until day 15 for RNA collection in Trizol (Invitrogen).
iPS cells grown in six-well Matrigel-coated plates to 100% confluence were released with Accutase for 30 secs, rinsed twice with PBS, and resuspended in mTeSR1 supplemented with 10 μM Y-27632. Cells (1 × 106 in 20 μl) were injected into 8–14 week-old male CB17 SCID mice (Charles River) under the testis capsule as described . A minimum of six testes were injected per iPS cell line. Tumors were collected 8–12 weeks after injection, fixed with 10% neutral buffered formalin for 24 hours, and processed for paraffin-embedded sections the Gladstone Histology and Microscopy Core or at the Division of Technical Support of the Institute for Frontier Medical Sciences in Kyoto University. All mouse studies were approved by the UCSF Institutional Animal Care and Use Committee, or performed in strict accordance with the Regulations on Animal Experimentation at Kyoto University.
Primary human MSCs were cultured in OB mineralization medium (DMEM with 20% FBS, glycerol-2-phosphate, 4 μM dexamethasone, 0.1 mM 2-mercaptoethanol, and 50 μg/ml L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate ). We could detect mineralization activity after 12 days as increased black staining by von Kossa (Additional file 2: Figure S1B), which was the preferred staining method used because the black mineralization nodules could be easily distinguished from the expected light golden-yellow staining of the cell layer. Human iPS cells maintained in feeder-free conditions were plated in 20% mTeSR1 mixed with 80% OB mineralization medium and Y-27632 (10 μM) at 2 million, 400,000, or 37,500 cells per well of gelatin-coated 6-, 24-, or 96-well plates, respectively. Medium was replaced on day two with 100% OB mineralization medium and changed every other day. Samples for von Kossa staining were fixed in 4% paraformaldehyde (PFA), stained in 5% silver nitrate for 15 minutes, and developed in 5% sodium carbonate/9.25% formaldehyde for two minutes. Regions of increased mineralization (dark black staining) can be seen at the edges of the well, where the culture surface meets the well wall. This was observed for all cell types and was excluded from staining intensity analysis. ImageJ (ver. 1.44o) was used for staining intensity analysis . DMH1 (4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline; from Dainippon-Sumitomo Pharma or Nacalai Tesque, Tokyo, Japan) was used at indicated concentrations; levels above 10 μM caused cell death. Scanning electron microscopy was performed on an Olympus TM3000 scanning electron microscope by the Gladstone Microscopy Core.
Pellet chondrogenic cultures were performed as described . Briefly, human iPS cells collected with a scraper were suspended as clumps in EB formation medium (DMEM, 10% Knockout Serum Replacement (KSR, Invitrogen), 10% FBS) and cultured for seven days on non-adherent bacterial petri dishes. The medium was changed every three days. EBs were landed onto 10-cm gelatin-coated tissue-culture dishes, grown to confluence, released with 0.25% trypsin/EDTA, filtered through a 70-μm cell strainer, and seeded onto new gelatin-coated dishes. Once confluent, cells were collected and 2.5 × 105 cells were placed into a 15-ml polypropylene tube, centrifuged at 1200 rpm for three min, and re-suspended in chondrogenic medium (high-glucose DMEM, with human 10 ng/ml TGF-β3, 100 nM dexamethasone, 6 μg/ml insulin, 100 μM ascorbic acid 2-phosphate, 1 mM sodium pyruvate, 6 μg/ml transferrin, 0.35 mM proline, and 1.25 mg/ml bovine serum albumin). Cells were re-centrifuged and maintained as a small pellet in the conical tubes for 28 days with medium changes every three days. Glycosaminoglycan content was quantified with BLYSCAN Dye and Dissociation reagents (BIOCOLOR, Belfast, UK). DNA content was quantified using a PicoGreen dsDNA quantitation kit (Invitrogen).
RT-PCR and quantitative PCR expression analysis
Semi-quantitative reverse transcription expression analysis of endogenous pluripotency genes, persistent expression of the retroviral iPS cell induction factors, episomal factors, or episomal gene expression, were performed on DNase-treated RNAs with the primers and PCR conditions as described [4, 8]. Quantitative PCR reactions were performed using 10 ng of reverse-transcribed cDNA in a final volume of 5 μl with ABI’s TaqMan Universal PCR Master Mix (Life Technologies) or ABI’s Syber Green PCR Master Mix at the recommended reagent ratios with the primers or probesets listed in Additional file 3: Table S2. Each reaction was run in technical triplicates on an Applied Biosystems 7900HT or Viia7 thermocycler (Life Technologies) and normalized to GAPDH as an endogenous control using protocols recommended by ABI.
Cells or EBs were fixed with 4% PFA/PBS for 10 min at room temperature, permeabilized with PBS/0.1% Triton X-100 for 10 min at room temperature, then blocked with 1% BSA. Representative lineages were detected with the following primary antibodies: SSEA3 (0.5 μg/ml, eBiosciences), TRA-1-60 (0.5 μg/ml, eBiosciences), TRA-1-81 (0.5 μg/ml, eBiosciences), NANOG (2 μg/ml, AF1997, R&D Systems), βIII-TUBULIN (1:100, MAB1637, Millipore), glial fibrillary acidic protein (1:500, Z0334, DAKO), α-smooth muscle actin (pre-diluted, N1584, DAKO), α-fetoprotein (2 μg/ml, MAB1368, R&D Systems), and tyrosine hydroxylase (1:100, AB152, Chemicon). Secondary antibodies were obtained from Invitrogen: Alexa488 or 555-conjugated goat anti-mouse IgG (1:200), Alexa488 or 555-conjugated goat anti-rabbit IgG (1:200), and Alexa488 or 555-conjugated donkey anti-goat IgG (1:200). Nuclei were stained with DAPI in the Vectashield set (Vector Laboratories).
Because each iPS cell line was derived clonally, and thus may display different behaviors, we treated each cell line as an individual biological replicate and pooled our results into controls or FOP categories. p values were calculated using the Student’s t-test or Dunnett multiple comparisons t-test. p values ≤ 0.05 were considered statistically significant.
ACVR1 R206H mutation is not sufficient to induce mineralization of fibroblasts
FOP patients show dramatic heterotopic bone formation in their soft tissues, yet do not ossify their skin. We asked if the ACVR1 R206H mutation  could induce mineralization in primary cells that do not normally form bone. Human dermal fibroblasts (HDFs) from control donors without known skeletal disease and FOP donors were cultured, genotyped (Additional file 2: Figure S1A), and propagated in HDF maintenance medium. For our mineralization assays, we used a culture medium that did not contain any exogenous BMPs that might mask the effects of the ACVR1 R206H mutation. This medium still promoted mineralization in primary human MSCs (Additional file 2: Figure S1B) when compared with standard non-mineralizing MSC maintenance medium. However, FOP HDFs showed no differences in mineralization activity when compared to HDFs cultured in non-mineralizing HDF maintenance medium, even with an additional 6 days of culture (Additional file 2: Figure S1C) and despite detectable increases in BMP-related phospho-SMAD levels in FOP HDFs (data not shown). Thus, the ACVR1 R206H mutation was not sufficient to induce spontaneous mineralization in HDFs in vitro.
Human iPS cells with the ACVR1 mutation are pluripotent
Isolating primary tissues from FOP patients is extremely difficult since injuries, including surgical procedures, induce bone formation flares. iPS cells derived from a small skin biopsy or excess surgical material provide a potential way to create a continuous supply of diseased tissues in vitro for experimentation. Since BMPs induce human ES cell differentiation , activated BMP signaling by the R206H ACVR1 mutation could adversely affect our ability to create FOP iPS cells. Fortunately our standard iPS cell culture media (mTeSR1) is free of BMPs, thus minimizing the potential activation of the hypersensitive R206H ACVR1 receptor by low levels of BMP.
We first created iPS cell lines from banked FOP skin fibroblasts (FOP1 and FOP2). Retroviruses with OCT4, SOX2, KLF4, and C-MYC were transfected into two control and two FOP fibroblast lines. We found a significant number of alkaline phosphatase-positive ES cell-like colonies from the FOP fibroblasts. Two control iPS cell lines (vWTa and vWTb) and four FOP iPS lines (vFOP1-1, vFOP1-4, vFOP2-1, and vFOP2-2) were characterized in detail and showed the expected genotypes (Figure 1A-D). All of the retroviral iPS cell lines suppressed the C-MYC and OCT3/4 transgenes (Figure 1E). Although low levels of exogenous KLF4 and SOX2 were detected in some lines, the iPS cell lines still expressed genetic markers of pluripotency (Figure 1F) and could form all three germ layers in teratomas (Figure 1G, Additional file 4: Figure S2A) and in EBs (Additional file 4: Figure S2B). While large amounts of cartilage were evident in several of the teratomas derived from FOP iPS cells, comparing the skeletal elements was not possible because of the heterogeneity of the internal structures, overall sizes, and maturity of each individual tumor, even from those derived from the same iPS cell line. All lines retained normal karyotypes (data not shown).
Retroviral FOP iPS cells show a trend to increased mineralization
Since FOP patients develop heterotopic endochondral bone formation, we tested if FOP and control iPS cells might have different predisposition to tissue mineralization in vitro. Retroviral FOP iPS cells cultured in mineralizing conditions showed a modest trend (p = 0.15 at 15 days) towards increased mineralization as assessed by von Kossa staining (Figure 2A-B). Using electron microscopy, we confirmed the presence of collagen-like fibers embedded in the mineral (Figure 2C-D), suggesting that the increased mineralization detected by von Kossa was not due to simple calcium/phosphate precipitation that can occur in cultured cell models . qPCR of the mineralizing iPS cells showed minimal changes in the expression of RUNX2, OSX, and OC in FOP and control iPS cells (Figure 2E), consistent with the relatively mild increase in mineralization. Thus, the vFOP iPS cells showed a trend towards increased mineral deposition by histology staining but surprisingly mild changes in gene expression patterns.
Persistent expression of exogenous transgenes in iPS cells has been reported and may be associated with partial reprogramming . To test if the ACVR1 R206H mutation favored iPS cells that retained expression of the inducing transgenes, and thus created partially-reprogrammed cells that were unable to fully show an osteogenic phenotype, we derived a second cohort of retroviral FOP iPS cell lines from fresh HDFs carefully isolated from two additional FOP patients (FOP4 and FOP5; Figure 3A-C). We used the vWT-TIG120-4f1, vWT-201B2, and vWT-201B7 iPS cell lines [4, 18] (here, preceded by vWT- for clarity) as controls. In this additional cohort, OCT3/4, SOX2, and KLF4 transgene expression was suppressed (Figure 3D), although a very faint band of C-MYC could be detected in vFOP4-1 by RT-PCR. However, quantitative PCR for transgene expression showed significant silencing of all transgenes relative to fibroblasts transduced with retrovirus (Additional file 5: Figure S3A). The vFOP4-1, vFOP4-3, and vFOP5-22 lines also formed teratomas containing all three germ layers (Additional file 5: Figure S3B), had normal karyotypes (Additional file 5: Figure S3C), expressed markers of pluripotency (Additional file 5: Figure S3D), and retained the ACVR1 R206H (617G > A) mutation (Figure 3C). Furthermore, differentiation of the iPS cells in the same mineralizing conditions used previously showed increased mineralization by histology (Figure 3E, F) and a similar gene expression pattern (Additional file 5: Figure S3E) as seen in the first cohort of retroviral iPS cells. Treating vFOP4-1 and vFOP5-22 iPS cells with the BMP signaling inhibitor DMH1 [19, 20] during culture could block the mineralization phenotype (Figure 3G, H).
FOP iPS cells show increased chondrogenesis
Since the second cohort of retroviral iPS cells showed better retroviral silencing characteristics, we used this set to test if the FOP mutation might affect chondrogenesis in a directed in vitro chondrogenesis assay. vFOP iPS cells cultured in 3-dimensional pellet cultures supplemented with TGF-β and dexamethasone  produced larger pellets with more ECM-containing chondrocyte-like cells than control iPS cells (Figure 4A, B). Glucose-amino-glycan (GAG) levels were 2–3-fold higher in vFOP iPS cell chondrocyte pellets than in controls (not shown). The vFOP4 and vFOP5 pellets also showed higher numbers of larger chondrocyte-like cells by morphology (Figure 4C-D). Quantitative PCR showed elevated mRNA levels of SOX9 and COL2a1 (markers of immature chondrocytes) and COMP (marker of mature chondrocytes) in the pellets (Figure 4E).
Integration-free FOP iPS cells also show increased mineralization
Since the degree of increased mineralization varied among the different batches of retroviral iPS cells with different levels of transgene silencing (Figures 2A and 3E), we created integration-free iPS cells to test if retroviral transgenes confound our ability to detect the effects of the ACVR1 R206H mutation. We used integration-free episomal vectors to introduce the iPS cell transformation factors SOX2, KLF4, OCT4, L-MYC, LIN28, and p53 shRNA into control and FOP dermal fibroblasts . We included an expanded collection of control dermal fibroblasts and FOP fibroblasts from skin removed during a medically-necessary surgical procedure (FOP3). We obtained a large number of FOP iPS cell colonies with morphology consistent with human ES cells (Figure 5A). Four lines from two control donors (eWT-1323-2, eWT-1323-4, eWT-BJ2, and eWT-BJ4) and six lines from three FOP donors (eFOP1-1, eFOP1-10, eFOP2-3, eFOP2-8, eFOP3-2, and eFOP3-4) were characterized in detail. All had normal karyotypes (Additional file 6: Figure S4A), retained the R206H ACVR1 mutation (Figure 5B), and expressed pluripotency markers by immunostaining (Additional file 7: Figure S5). Five of the six FOP lines had normal teratoma formation (Figure 5C, Additional file 6: Figure S4B). Line eFOP2-8 lacked clear mature endodermal elements and was excluded from further analyses. Expression analysis suggested eFOP3-4 had low levels of OCT4 plasmid expression; however, no retained episomal vectors were found by genomic DNA qPCR for the EBNA gene which is located in the episome backbone (Additional file 6: Figure S4C, D). The FOP lines had higher levels of phospho-SMAD 1/5/8 before and after stimulation with BMP4 (Figure 5D), showing responsiveness to exogenous BMP.
eFOP iPS cells cultured in mineralization medium had significantly increased mineralization activity at day 6 by von Kossa staining (Figure 6A, B), but this difference narrowed by day 12. We found no statistical difference in wildtype ACVR1 expression even though the R206H ACVR1 allele expression decreased significantly over the course of the experiment (Figure 6C). ID1 and DLX5, both activated by BMP signaling, were increased at day 6, indicating that the ACVR1 R206H mutation increased activation of BMP signaling (Figure 6D). Expression analysis showed a trend towards transient increases of chondrogenic markers COLLAGEN 2 (COL2a1) as well as increased expression of the osteogenic marker OSTEOCALCIN (OC) at day 6 (Figure 6E, F). The FOP iPS cells showed no significant increase in expression of early markers of chondrogenesis (SOX9) or osteogenesis (RUNX2) at the time points we assayed; in fact, levels of these early markers were higher in control iPS cells as compared to the FOP iPS cells (Figure 6E, F). FOP iPS cells also showed increased expression of genes associated with mineralization activity (Figure 6F), such as alkaline phosphatase. In addition, we found increased expression of TFIP11, a ubiquitously expressed gene that suppresses chondrocytic development, may function during the transition from a cartilage template towards the formation of ossification centers  and may regulate tooth enamel deposition . These in vitro results suggest that the ACVR1 R206H mutation confers increased propensity towards mineral deposition, possibly via a mineralized cartilage mechanism with transient increases in osteogenic markers.
Here, we use human iPS cells derived from FOP donors to establish a cellular foundation to understand the mechanisms underlying this dramatic disease (Figure 7). Our FOP iPS cells are a valuable in vitro human model system for understanding how human bone develops and identifying what control points may be amenable for manipulating normal and pathologic bone formation. The iPS cells will also facilitate identifying the triggers of heterotopic bone formation and strategies to block the different steps of mineralization or ossification, particularly by providing the ability to create key human cell types not directly available from the FOP patients or from patient progenitor cells. These iPS cells also provide a unique human-specific perspective that complements the in vivo studies of the FOP mouse model . In this study, we created and analyzed three sets of independently-derived iPS cell lines. Our results suggest that generating iPS cells with integration-free methods rather than retroviral methods may decrease the likelihood of confounded results from persistent transgene expression, as has been described for C-MYC.
Our findings indicate that the ACVR1 R206H mutation can allow human iPS cells to form chondrocytes and mineralize in vitro without a clear fibro-proliferative stage as in FOP patients. Since the fibro-proliferative cells in an early FOP lesion are likely a collection of diverse cell types, we speculate that more primitive cell types or early skeletal precursors, such as those potentially in our iPS cell model, could be major contributors to the early FOP lesion. Although this might explain the mineralization that occurred without altered osteogenic markers, further experiments are needed to delineate the distinct effects of ACVR1 R206H on mineralization and osteogenesis in our iPS cell model.
Our results also suggest that the ACVR1 R206H mutation may have greater influence earlier in endochondral bone formation (i.e., at the chondrogenesis stage) based on gene expression patterns. Although ACVR1 can be regulated by miR-148a , the decreasing levels of ACVR1 R206H mRNA during mineralizing culture suggest that the 617 G > A mutation confers allele-specific regulation of RNA transcripts. However, the heterogeneity of our iPS cell mineralization cultures precluded us from identifying if a specific cell type is down-regulating ACVR1 R206H expression during culture. Delineating this potential regulatory function using FACS-purified cells or iPS cell-derived cell types could identify more specific roles for ACVR1 in bone formation and identify a new therapeutic target that would complement strategies to modulate the signaling properties of the ACVR1 receptor.
Although we could identify differences in mineralization by the FOP iPS cells, our simple culture conditions may not fully recapitulate the requirements for forming mature osteogenic cells from iPS cells. Similar challenges for creating mature cell types have been identified using current culture methods in other types of ES or iPS cell-derived progeny  and in some mesenchymal stem cell culture conditions . This could account for the low expression levels of osteogenic genes. Instead, our culture conditions may better reflect the early steps of matrix mineralization in injured cartilage. The increased expression of genes associated with mineralization activity, such as TFIP11 and alkaline phosphatase, suggest the ACVR1 R206H mutation can direct mineral deposition in tissues. This is consistent with reports indicating that BMP signaling increases mineralization activity in other cell types . Bone formation and mineralization can also occur in the absence of osteoblasts in Osx-deficient mice [29, 30].
Future studies will benefit from newer 3D scaffolds, the creation of multi-cellular bone models with iPS cell–derived cell types, better defined culture conditions, and in vivo translational assays which may favor the formation of mature skeletal cells. These directions will help identify the factors that may act at different stages of osteogenesis, including those that initiate heterotopic bone formation and lead to the formation of mature skeletal elements in humans. In addition, our results suggest that blocking mineralization induced by ACVR1 R206H may be a useful treatment strategy for preventing full mineralization of heterotopic bone lesions in FOP patients, thus preserving some limited joint mobility even if cartilage formation still occurs.
The increased chondrogenesis and mineralization, as well as the trend towards increased expression of endothelial cell gene markers, raise the possibility that the R206H ACVR1 mutation promotes skeletogenesis by affecting cell fate. Several observations support this notion. Studies in connective tissue progenitor cells from discarded primary teeth (SHED cells) of FOP patients with the ACVR1 R206H mutation show enhanced osteogenic differentiation . In addition, introducing the R206H ACVR1 mutation into endothelial cells can increase endothelial-mesencymal transition and promote entry into an osteogenic lineage , possibly contributing to the bone formation in FOP. Finally, BMP activation induces differentiation in human ES cells . These results suggest that activating the BMP signaling pathway may affect a cell’s ability to retain cell-fate commitment under specific circumstances.
Our studies showed that pluripotent FOP iPS cells can be generated without a BMP inhibitor using either the retrovirus or episomal methods. Prior attempts to make iPS cells from FOP fibroblasts by the Sendai virus method showed cellular instability . This could be partially mitigated by culturing the cells with a BMP inhibitor, making the iPS cell formation process a useful assay for identifying small molecules that affect ACVR1 signaling. Although our study was not designed to directly compare the different iPS cell-generating methods, our results identify two major implications. First, our findings suggest that different pluripotency induction techniques, culture conditions, or embryonic fibroblast feeder cells could influence the success of iPS cell generation. Although Sendi virus can efficiently express reprogramming factors, the steps needed to remove replicating virus from cultures and the sensitivity of the viral RNA replicase to transgene sequences may contribute to different overall efficiencies of iPS cell generation . Furthermore, the conditions under which iPS cells are derived, including the specific feeder cells used, can affect important aspects such as gene expression, reprogramming efficiency, and X-inactivation . These observations indicate that the specific iPS cell derivation conditions may significantly affect the ability to generate iPS cell lines particularly if a disease mutation affects cell fate stability. Second, our study applies the FOP iPS cells as a disease model to demonstrate a potential function for ACVR1 in chondrogenesis and mineralization. These two endpoints may be useful for screening drug modulators that target different stages of human osteogenesis, particularly once the chondrogenic potential of the episomal iPS cells has been determined. Further studies to identify if cell fate stability is affected in non-pluripotent cells such as chondrocytes or osteoblasts may also reveal if cell fate plays a key role in the pathogenesis of heterotopic ossification in FOP.
Our iPS cell strategy provides a key first step towards dissecting the cellular and molecular mechanisms of human skeletal disease pathogenesis in FOP. Human iPS cells will also be a valuable tool that reflects the diversity of patients we see in the clinic since patients, and thus, their iPS cells show clinical variability, genetic background effects, and epigenetic influences. Creation of new isogenic controls by gene correction , combined with translational genetic studies and correlations with murine models, provides exciting venues for new strategies to understand the stages of normal and pathologic human skeletal development. Our studies demonstrate the creation of iPS cells from patients with FOP, identify that ACVR1 may have a new role in regulating mineralization activity, and provide a proof-of-concept for further development of human iPS cells as disease models for studying human skeletal diseases.
Bone morphogenetic protein
Embryonic stem cells
Fibrodysplasia ossificans progressiva
Human dermal fibroblast
Induced pluripotent stem cells
Mesenchymal stem cells.
We thank Gary Howard, Matt Spindler, Kenta Nakamura, Wint Lwin, Will Collins, Kathy Ivey, Ashley Urrutia, Nathalie Gaborit, Sanae Nagata, Deepak Srivastava, Eileen Shore, the Gladstone Stem Cell Core, and the UCSF Stem Cell Core for valuable technical assistance and discussions. We gratefully acknowledge the contributions of the participants in our study. This work was supported by NIH R01 HL60664 to BRC; NIH K08 AR056299, California Institute of Regenerative Medicine/Gladstone Institutes CIRM Fellowship (#T2-00003), UCSF Department of Medicine, and March of Dimes Basil O’Connor Starter Grant (#5-FY12-167) to ECH; the Duke-NUS Graduate Medical School Singapore 3rd-year Research Program to CRS; a California Institute of Regenerative Medicine/UCSF CIRM Fellowship (#TG2-01153) to EB; Grants-in-aid for Scientific Research from JSPS (#23791636, #25293320), the Leading Project for Realization of Regenerative Medicine from MEXT, and The Program for Intractable Diseases Research utilizing Disease-specific iPS cells from JST in part to MI and JT; the Uehara Memorial Foundation and USCF Program for Breakthrough Biomedical Research to YH; and the Leading Project of MEXT, Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program) of the JSPS, Grants-in-Aid for Scientific Research of the JSPS and MEXT, Program for Promotion of Fundamental Studies in Health Sciences of NIBIO, L.K. Whittier Foundation, and Rodenberry Foundation to SY. SY is a member without salary of the scientific advisory boards of iPierian, iPS Academia Japan, Megakaryon Corporation, and HEALIOS K.K., Japan. BRC is on the Scientific Advisory Board of iPierian, Inc. The funders had no role in study design, data collection/analysis, decision to publish, or preparation of the manuscript.
Department of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University
Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Nagoya City University
Gladstone Institute of Cardiovascular Disease
Department of Medicine, Duke-NUS Graduate Medical School
Department of Medicine, Division of Endocrinology and Metabolism and the Institute for Human Genetics, University of California-San Francisco
Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University
Department of Fundamental Cell Technology, Center for iPS Cell Research and Application, Kyoto University
Department of Reprogramming Science, Center for iPS Cell Research and Application, Kyoto University
Department of Medicine and Cellular and Molecular Pharmacology, University of California-San Francisco
Reddi AH, Cunningham NS: Initiation and promotion of bone differentiation by bone morphogenetic proteins.J Bone Miner Res 1993,8(Suppl 2):S499-S502.PubMed
Bostrom KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y: Activation of vascular bone morphogenetic protein signaling in diabetes mellitus.Circ Res 2011, 108:446–457.PubMed CentralPubMedView Article
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell 2007, 131:861–872.PubMedView Article
Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, et al.: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.Nat Genet 2006, 38:525–527.PubMedView Article
Shen Q, Little SC, Xu M, Haupt J, Ast C, Katagiri T, Mundlos S, Seemann P, Kaplan FS, Mullins MC, Shore EM: The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization.J Clin Invest 2009, 119:3462–3472.PubMed CentralPubMed
Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, et al.: A more efficient method to generate integration-free human iPS cells.Nat Methods 2011, 8:409–412.PubMedView Article
Byrne JA, Nguyen HN, Reijo Pera r: Enhanced generation of induced pluripotent stem cells from a subpopulation of human fibroblasts.PLoS One 2009, 4:e7118.PubMed CentralPubMedView Article
Shibata KR, Aoyama T, Shima Y, Fukiage K, Otsuka S, Furu M, Kohno Y, Ito K, Fujibayashi S, Neo M, et al.: Expression of the p16INK4A gene is associated closely with senescence of human mesenchymal stem cells and is potentially silenced by DNA methylation during in vitro expansion.Stem Cells 2007, 25:2371–2382.PubMedView Article
McMahon AP, Bradley A: The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain.Cell 1990, 62:1073–1085.PubMedView Article
Karner E, Unger C, Sloan AJ, Ahrlund-Richter L, Sugars RV, Wendel M: Bone matrix formation in osteogenic cultures derived from human embryonic stem cells in vitro.Stem Cells Dev 2007, 16:39–52.PubMedView Article
Abramoff MD, Magelhaes PJ, Ram SJ: Image processing with ImageJ.Biophoton Int 2004, 11:36–42.
Nasu A, Ikeya M, Yamamoto T, Watanabe A, Jin Y, Matsumoto Y, Hayakawa K, Amano N, Sato S, Osafune K, et al.: Genetically matched human iPS cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin.PLoS One 2013, 8:e53771.PubMed CentralPubMedView Article
Xu RH, Peck RM, Li DS, Feng X, Ludwig T, Thomson JA: Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells.Nat Methods 2005, 2:185–190.PubMedView Article
Bonewald LF, Harris SE, Rosser J, Dallas MR, Dallas SL, Camacho NP, Boyan B, A B: von Kossa staining alone is not sufficient to confirm that mineralization in vitro represents bone formation.Calcif Tissue Int 2003, 72:537–547.PubMedView Article
Hotta A, Ellis J: Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states.J Cell Biochem 2008, 105:940–948.PubMedView Article
Ao A, Hao J, Hopkins CR, Hong CC: DMH1, a novel BMP small molecule inhibitor, increases cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells.PLoS One 2012, 7:e41627.PubMed CentralPubMedView Article
Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, Hopkins CR, Lindsley CW, Hong CC: In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.ACS Chem Biol 2010, 5:245–253.PubMed CentralPubMedView Article
Panda D, Goltzman D, Juppner H, Karaplis AC: TIP39/parathyroid hormone type 2 receptor signaling is a potent inhibitor of chondrocyte proliferation and differentiation.Am J Physiol Endocrinol Metab 2009, 297:E1125-E1136.PubMedView Article
Paine CT, Paine ML, Luo W, Okamoto CT, Lyngstadaas SP, Snead ML: A tuftelin-interacting protein (TIP39) localizes to the apical secretory pole of mouse ameloblasts.J Biol Chem 2000, 275:22284–22292.PubMedView Article
Chakkalakal SA, Zhang D, Culbert AL, Convente MR, Caron RJ, Wright AC, Maidment AD, Kaplan FS, Shore EM: An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.J Bone Miner Res 2012, 8:1746–1756.View Article
Song H, Wang Q, Wen J, Liu S, Gao X, Cheng J, Zhang D: ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a.Int J Mol Sci 2012, 13:2063–2077.PubMed CentralPubMedView Article
Patterson M, Chan DN, Ha I, Case D, Cui Y, Van Handel B, Mikkola HK, Lowry WE: Defining the nature of human pluripotent stem cell progeny.Cell Res 2012, 22:178–193.PubMedView Article
Cordonnier T, Langonne A, Sohier J, Layrolle P, Rosset P, Sensebe L, Deschaseaux F: Consistent osteoblastic differentiation of human mesenchymal stem cells with bone morphogenetic protein 4 and low serum.Tissue Eng Part C Methods 2011, 17:249–259.PubMedView Article
Hughes-Fulford M, Li CF: The role of FGF-2 and BMP-2 in regulation of gene induction, cell proliferation and mineralization.J Orthop Surg Res 2011, 6:8.PubMed CentralPubMedView Article
Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B: The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.Cell 2002, 108:17–29.PubMedView Article
Zhou X, Zhang Z, Feng JQ, Dusevich VM, Sinha K, Zhang H, Darnay BG, de Crombrugghe B: Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice.Proc Natl Acad Sci U S A 2010, 107:12919–12924.PubMed CentralPubMedView Article
Billings PC, Fiori JL, Bentwood JL, O’Connell MP, Jiao X, Nussbaum B, Caron RJ, Shore EM, Kaplan FS: Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP).J Bone Miner Res 2008, 23:305–313.PubMedView Article
Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR: Conversion of vascular endothelial cells into multipotent stem-like cells.Nat Med 2010, 16:1400–1406.PubMed CentralPubMedView Article
Hamasaki M, Hashizume Y, Yamada Y, Katayama T, Hohjoh H, Fusaki N, Nakashima Y, Furuya H, Haga N, Takami Y, Era T: Pathogenic mutation of Alk2 inhibits Ips cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.Stem Cells 2012, 30:2437–2449.PubMedView Article
Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M: Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome.Proc Jpn Acad Ser B Phys Biol Sci 2009, 85:348–362.PubMed CentralPubMedView Article
Tomoda K, Takahashi K, Leung K, Okada A, Narita M, Yamada NA, Eilertson KE, Tsang P, Baba S, White MP, et al.: Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells.Cell Stem Cell 2012, 11:91–99.PubMed CentralPubMedView Article
Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, et al.: Genetic engineering of human pluripotent cells using TALE nucleases.Nat Biotechnol 2011, 29:731–734.PubMed CentralPubMedView Article
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.